After homing to the tumor site, CAR T cells must undergo abundant expansion in order to eliminate the tumor in vivo. The major predictors of the clinical efficacy of CAR T cells are the proliferation and persistence of the T cells. Vast clinical trials of CAR T cell therapy have demonstrated poor persistence of T cells transfused in vivo, especially in solid tumors [
16]. Therefore, improving the expansion and persistence of CAR T cells is the focus of current research.
Costimulatory signaling domain optimization
Considerable efforts have been concentrated on the optimization of CAR constructs to enhance costimulatory signaling. The incorporation of one or more costimulatory signaling domains (CSSDs), such as CD28 [
37], 4-1BB [
38], OX40 [
39], CD27 [
40], or ICOS [
41], can enhance the proliferation, persistence, and effector function of CAR T cells. The selection of costimulatory molecules also impacts the kinetics, tumoricidal profile, and safety of CAR T cells. Therefore, understanding the characteristics of known and emerging costimulatory signal domains is essential for improving the efficacy of CAR T cell therapy.
CD28 and 4-1BB are the most widely tested costimulatory domains in clinical trials [
42]. CD28-based CAR T cells are associated with more rapid T cell proliferation and tumor elimination, while CAR T cells expressing the 4-1BB domain possess noticeably slower kinetics, but greater persistence [
43]. Compared with CD28, ICOS costimulation induces a greater increase in PI3K activity [
44] and drives CAR T cells to differentiate into Th17/Th1 cells [
45]. Analogous to 4-1BB-based CARs, CD27-based CARs lead to enhanced persistence compared with CD28-based CARs [
40]. The specific combination of costimulatory domains also has an impact on CAR T cell activity. PSMA-CAR T cells bearing both CD28 and 4-1BB display the strong PI3Kinase/Akt activation, relevant to reduced apoptosis and enhanced effector function of CD8
+ T cells [
46]. Although a third generation CD28-OX40-CD3ζ CAR T cell increases the production of IL-2 and IL-10 [
39], CAR T cells with a CD28-CD3ζ-OX40 construct show the opposite result [
47]. Analogously, ICOS-4-1BB-CD3ζ CAR (ICOSBBz) produces more IL-7 and IL-10, whereas the reverse CAR (BBICOSz) produces more IL-6 and IL-13, suggesting that the membrane-proximal domain is of great importance in determining cytokine secretion [
48]. In order to further explore the functional characteristics and clinical efficacy, various clinical trials on the second or third generation CARs above have been carried out, involving multiple antigen targets and tumor types [
49] (Table
1).
Table 1
Summary of costimulatory molecules in CAR T cell trials for solid tumors
CD28 | Increased cytokine production; more potent effector function; more rapid T cell proliferation and tumor elimination [ 43] | Lewis Y | Advanced solid cancer | NCT03851146 | I | Recruiting | 30 | Peter MacCallum Cancer Centre |
Chlorotoxin | Glioma | NCT04214392 | I | Recruiting | 36 | City of Hope Medical Center |
HER2 | Sarcoma | NCT00902044 | I | Active, not recruiting | 36 | Baylor College of Medicine |
| Glioblastoma | NCT01109095 | I | Completed | 16 | Baylor College of Medicine |
4-1BB | Greater persistence; increased central memory T cell generation [ 43] | PSCA | Prostate cancer | NCT03873805 | I | Recruiting | 33 | City of Hope Medical Center |
PD-L1 | Lung cancer | NCT03330834 | I | Recruiting | 22 | Sun Yat-sen University |
Mesothelin | Pancreatic cancer | NCT03638193 | I | Recruiting | 10 | Shenzhen BinDeBio Ltd. |
| MPM | NCT01355965 | I | Completed | 18 | University of Pennsylvania |
| Ovarian cancer | NCT02159716 | I | Completed | 19 | University of Pennsylvania |
GPC3 | Hepatocellular cancer | NCT02715362 | I/II | Recruiting | 30 | Shanghai GeneChem Co Ltd. |
IL13Ralpha2 | Melanoma | NCT04119024 | I | Recruiting | 24 | Jonsson Comprehensive Cancer Center |
| Glioblastoma | NCT04003649 | I | Recruiting | 60 | City of Hope Medical Center |
CEA | Liver metastases | NCT02862704 | I/II | Recruiting | 20 | Xijing Hospital |
CD171 | Neuroblastoma | NCT02311621 | I | Recruiting | 40 | Seattle Children’s Hospital |
MET | Melanoma | NCT03060356 | I | Terminated | 77 | University of Pennsylvania |
| Breast cancer | NCT03060356 | I | Terminated | 77 | University of Pennsylvania |
EGFRvIII | Glioblastoma | NCT03726515 | I | Active, not recruiting | 7 | University of Pennsylvania |
CD28 and 4-1BB | Strong PI3Kinase/Akt activation; reduced apoptosis of CD8+ T cells; enhanced effector function of CD8 + T cells [ 46] | CD171 | Neuroblastoma | NCT02311621 | I | Recruiting | 40 | Seattle Children's Hospital |
CD28 and OX40 | CD28-OX40-CD3ζ CAR increased the production of IL-2 and IL-10; CD28-CD3ζ-OX40 CAR decreased the production of IL-2 and IL-10 [ 39, 47] | GD2 | Neuroblastoma | NCT01822652 | I | Active, not recruiting | 11 | Baylor College of Medicine |
Sarcoma | NCT01953900 | I | Active, not recruiting | 26 | Baylor College of Medicine |
In addition to known costimulatory molecules, other more novel costimulatory molecules are under active exploration. There is accumulating evidence demonstrating a critical role of herpesvirus entry mediator (HVEM, TNFRSF14) in the memory development of T cells [
50]. CAR T cells bearing an HVEM-derived CSSD display the greater effector function than those with CD28- or 4-1BB-derived CSSD, which may be due to the reduced T cell exhaustion, reprogrammed energy metabolism and balanced differentiation of memory T cell subsets [
51]. Toll-like receptor 2 (TLR2) is known to strengthen the effector function and proliferation of CD8
+ T cells and reduce the activation threshold of costimulatory signaling [
52,
53]. By adding TLR2 to the 3′ end of m28z CAR (m28zT2 CAR), the resulting CAR T cells exhibit enhanced cytotoxicity and expansion capacity and lower expression levels of exhaustion markers [
54]. However, various degrees of cytokine release syndrome (CRS) occurred in patients receiving 1928zT2 CAR T cells [
55], suggesting that more clinical trials are required to monitor their side effects. Natural killer group 2 member D is a strong costimulatory receptor expressed on NK and CD8
+ T cells [
56]. It can transmit an activating signal in T cells, via the adaptor protein, DNAX-activating protein 10 (DAP10), leading to memory formation and enhanced inflammatory cytokine production in CD8
+ T cells [
57,
58]. Thus, DAP10 incorporation into the 3′ end of CAR indeed improves the antitumor activity of CAR T cells against lung cancer, hepatocellular carcinoma, and gastric cancer in mouse models [
59,
60]. Both TLR2 and DAP10 incorporation can elevate the expression of T-bet, a transcription factor mediating T cell differentiation, which provides a direction for exploring new costimulatory molecules. Collectively, these findings underscore the importance of optimizing costimulatory molecules in CAR T cells.
Thus, the CSSD is crucial for modulating CAR T cell activity. More significantly, elucidating the mechanistic and biological differences of costimulatory molecules and determining the optimal CSSD combination will be a top priority in future studies.